https://www.avient.com/knowledge-base/article/could-polyketone-be-next-generation-nylon-alternative?utm_source=linkedin&utm_medium=social&utm_campaign=LinkedIn-Organic-General
Aliphatic polyketone, often referred to as just polyketone or PK, is a semi-crystalline engineering resin that is an alternating copolymer of carbon monoxide and ethylene with some propylene (1–10%).
In each case, the physical property retention of Avient’s PK-based formulations was superior to that of PA6 or PA66.
However, Avient has overcome this challenge and achieved vibrant colors like any other resin.
https://www.avient.com/industries/healthcare/drug-delivery-systems/inhalation-devices
Office Supplies
Pet Care & Supplies
Auto-injectors and Drug Delivery Pens
https://www.avient.com/industries/healthcare/remote-monitoring-wearables/home-care-monitors
Office Supplies
Pet Care & Supplies
Auto-injectors and Drug Delivery Pens
https://www.avient.com/company/policies-and-governance/ethics-hotline
If you have concerns about Avient business practices, visit our dedicated Ethics Hotline or call +1-877-228-5410.
Avient Supplier Information
Supplier Code of Conduct
https://www.avient.com/industries/healthcare/catheter-materials-medical-tubing/medical-tubing
Office Supplies
Pet Care & Supplies
Auto-injectors and Drug Delivery Pens
https://www.avient.com/industries/healthcare/drug-delivery-systems/prefilled-syringes
Office Supplies
Pet Care & Supplies
Auto-injectors and Drug Delivery Pens
https://www.avient.com/sites/default/files/2023-07/AVNT Q2 2023 Earnings Presentation%5B70%5D.pdf
Pro Forma Financial Information
The Company acquired Avient Protective Materials (“Dyneema”) on September 1, 2022 (the “Acquisition Date”) and sold the Distribution segment on November 1, 2022.
Avient reflects 2023 adjusted EBITDA guidance of $525M and estimated run-rate CAPEX of $110M.
2023E (%)
23
79
90
84 83
76
73
88
82
77
74 72
67
57
20
Avient Specialty
Other Specialty /
MULTIPLE EXPANSION
Note: Avient reflects 2023 adjusted EBITDA guidance of $525M and closing share price of $40.93.
Avient 2011 and 2018 valuations reflect trailing 12 months EBITDA at December 31 of the respective years.
24
EV / 2023E EBITDA
Historic Multiple
6.5
8.3
10.3
14.4
13.6 13.6
12.4
9.0
20.2
18.2
11.5
10.6
9.7 9.6
8.7 8.3
01
1)
01
8)
02
3)
Avient Specialty
Other Specialty /
SEGMENT DATA
U.S. & Canada
40%
37%
18%
2022 PRO FORMA SEGMENT, END MARKET AND GEOGRAPHY
GEOGRAPHY REVENUESEGMENT FINANCIALS
20%
24%
Building and
END MARKET REVENUE
$2,355M $402M
$1,300M $272M
Sales EBITDA
Specialty Engineered Materials
Color Additives and Inks
$592M$3,653M
(1)
9%
26
(1) Total company sales and adjusted EBITDA of $3,653M and $592M, respectively, include intercompany sales eliminations and corporate costs
2022 REVENUE | $2 .4 B ILL ION
34%
38%
20%
END MARKET REGION
27
34%
21%
Building &
1% Energy
2%
COLOR, ADDITIVES & INKS
2022 PRO FORMA REVENUE | $1 .3 B ILL ION
52%
35%
28
19%
8%Industrial
16%
9% Defense
Building &
END MARKET REGION
SPECIALTY ENGINEERED MATERIALS
32%
27%
14%
Building &
3%
1% Defense
1%
(18% of sales)
9%
2022 PROFORMA AVIENT REGIONAL SALES
27%
14%
17%
Building &
(37% of sales)Transportation
24%
12%
Building &
US &
Canada
(40% of sales)
7%
56%
23%
7%
Building &
1%
LATAM
(5% of sales)
3%
29
BY END MARKET
Reconciliation of Non-GAAP Financial Measures
(Unaudited)
(Dollars in millions, except for per share data)
Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders
and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special
items, to assess performance and facilitate comparability of results.
https://www.avient.com/resource-center?document_subtype=127&document_type=59&form_build_id=form-Ojq3VtEkRrXIsgZSyKvAgO_Z3JHuKtjJLR7xfOXoAI8&form_id=resource_filter_form&industry=0&op=FILTER RESULTS&product_family=81&product_name=0&product_subfamily=0&page=1
Avient Resources
Avient Resources
Auto-Injector Housing - Medical Delivery Device
https://www.avient.com/resource-center?document_type=59&document_subtype=127&industry=0&product_family=81&product_subfamily=0&product_name=0&op=FILTER RESULTS&form_build_id=form-Ojq3VtEkRrXIsgZSyKvAgO_Z3JHuKtjJLR7xfOXoAI8&form_id=resource_filter_form&page=1
Avient Resources
Avient Resources
Auto-Injector Housing - Medical Delivery Device
https://www.avient.com/sites/default/files/2022-07/Avient Announces Second Quarter 2022 Results_1.pdf
Overall, we are pleased with our performance as we have been able to overcome a number of
continuing challenges including inflation, supply chain disruptions, extended lockdowns in China
and the war in Ukraine,” said Robert M.
# #
Investor Relations Contact:
Giuseppe (Joe) Di Salvo
Vice President, Treasurer and Investor Relations
Avient Corporation
+1 440-930-1921
giuseppe.disalvo@avient.com
Media Contact:
Kyle G.
Rose
Vice President, Corporate Communications
Avient Corporation
+1 440-930-3162
kyle.rose@avient.com
mailto:giuseppe.disalvo@avient.com
mailto:giuseppe.disalvo@avient.com
mailto:kyle.rose@avient.com
6
Attachment 1
Avient Corporation
Summary of Condensed Consolidated Statements of Income (Unaudited)
(In millions, except per share data)
Three Months Ended
June 30,
Six Months Ended
June 30,
2022 2021 2022 2021
Sales $ 1,302.4 $ 1,235.2 $ 2,596.2 $ 2,397.5
Operating Income 129.5 108.1 258.1 228.5
Net income attributable to Avient shareholders 84.7 68.8 168.9 148.1
Basic earnings per share attributable to Avient shareholders $ 0.93 $ 0.75 $ 1.85 $ 1.62
Diluted earnings per share attributable to Avient shareholders $ 0.92 $ 0.74 $ 1.83 $ 1.60
Senior management uses comparisons of adjusted net income attributable to Avient shareholders and diluted adjusted earnings
per share (EPS) attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability
of results.